Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development
|
|
- Violet Allison
- 8 years ago
- Views:
Transcription
1 Rapid Pharma Development GmbH Impurities in the contexts of CMC Development
2 The Challenge What is your Goal? What is your path?
3 Plan for Success Define your goal: Target Product Profile Daily dosage Cost of Goods Administration Route Define your path: Project Plan Work backwards: NDA submission, Clinical Studies, IND, Tox Studies,.. Material needs for preclinical and clinical studies
4 Drug Development Summit CTD: Common Technical Document Module 1 Regional Admin Information TOC Introduction Module 2 CMC part Overall Quality Summary non clinical Overview non-clinical Summary clinical Overview Clinical Summary Module 3 Module 4 Module 5 Quality Nonclinical Study Reports Clinical Study Reports
5 Quality Statement drugs should be safe, pure, effective and of consistent quality to ensure that they are fit to be used for their intended purpose
6 Clinical Hold Quality Concerns that cause a Clinical Hold are either e.g. 1. identification of safety concern or 2. insufficient data to evaluate safety toxic impurities (solvents, genotoxics) instability during the course of the clinical trial generating toxic impurities insufficient analytical effort
7 The Guidelines Sources on the net: Q3A(R2) Impurities in New Drug Substances Q3B(R2) Impurities in New Drug Products Q3C(R4) Impurities: Guideline for Residual Solvents
8 Impurities Organic Manufacturing Origin sm, intermediates, reagents, byproducts Storage Origin (Degradants) hydrolysis (acidic, basic), oxidation, thermal >0.05 % have to be reported in phase I rrt >0.1% identified, response factors known Typically HPLC with UV detection to quantify these
9 Special Cases Solvents (Q3C) Inorganics (metals, salts, glass, charcoal) Genotoxics (draft guidance Dec 2008) Enantiomers (considered as known impurity, but qualification of high levels possible) Polymorphs (solid state form has to be controlled, bioavailability is effected)
10 Solvents PDE based Click on to 10 edit g daily Master dosage title style Acetonitrile 4.1 mg/day (410 ppm) daily dosage 500 mg -> up to 0.82 wt% acceptable Class I don t use: Benzene, CCl4 Class II: control THF 7.2 mg/day NMP 5.3 mg/day Class III: 0.5% MTBE, EtOAc, Ethanol, Propanol
11 Genotoxics Terminology PGI potentially genotoxic impurity: Compounds with Structure Alerts Genotoxic Compound: Compounds that cause damage to DNA Mutagenic: DNA impact that is tranferred from cell to cell Genotoxic and Mutagenic: Ames Test and other assays Carcinogenic: long term studies -> genotoxic = potential carcinogen
12 Genotoxic Levels TTC threshold Click toxicological edit Master concern title style 1.5 μg/d ->1 g 1.5 ppm FDA: Draft Guidance Dec 2008 EMA: CPMP/SWP/5199/02 June 2006
13 Decision Tree
14 Structural Alerts
15 Not all Alerts are positive
16 Influence of Chemists Try to avoid Genotoxic Impurities
17 Salt Formation: Mesylates Source: Teasdale et al. Org. Process Res. Dev. 2010, 14,
18 Alkylhalides Generally: The presence of a strong acid together with an alcohol may generates a PGI. E.g. HBr as byproduct in a condensation reaction If early in a synthesis typically these PGI are purged. Late in the synthesis may be a concern In all cases develop suitable analytical methods LS-MS GC-MS are typical work horses Q. Yang et al. Org. Process Res. Dev., 2009, 13, pp
19 Genotoxic as reagents How to avoid dibromoethane! but then what about the Styrene oxide? And how did they make 16? Butters et al. Chem. Rev. 2006, 106,
20 Aromatic Anilines B. Mayes et al. Org. Process Res. Dev., 2010, 14 (5), pp
21 Hidden PGI hydrolysis Byproduct itself may not be detected as PGI, but on stability or during next steps, or drug product manufacturing wet granulation, the PGI may rebuild.
22 Stability Studies S. Raillard et al. Org. Process Res. Dev., 2010, 14 (4), pp
23 Generics Quelle: D.D. Wirth, B.A. Olsen, D.K. Hallenbeck, M.E. Lake, S.M. Gregg und F.M. Perry, Chromatographia, 1997, 46,
24 Excipients Excipient Povidone, crospovidone polysorbates Magnesium stearate, fixed oils, lipids Lactose Benzylalcohol Polyethyleneglycol Microcrystalline Cellulose Starch Talc Dibasic calcium phosphate dihydrate Stearate lubricants Hydroxypropyl methyl/ethyl cellulose Residue (Impurity) Peroxides Antioxidants Aldehydes, reducing sugars Benzaldehyde Aldehydes, peroxides, oeganic acids Lignin, hemicelluloses, water Formaldehyde Heavy metals Alkaline residues Alkaline residues Glyoxal Source: Crowley, P.J.; Martini, L.G.; Drug-Excipient Interactions, Pharmaceutical Technology Oct 2001
25 Conclusion A chemist should aim to avoid PGI as reagents, starting materials, byproducts, synthetic intermediates Generics and Excipients should receive more attention by regulatory agenices Analytical Methods can only find what you are looking for Stability Studies: Degradants may also form PGI Recommended Reading: D. Snodin Org. Process Res. Dev., 2010, 14,
26 Conclusion Drug Master File Chemistry Manufacturing Control Knowledge and Experience Don t build your house without an architect
27
28 The architects Dr. Dieter Krimmer Managing Partner at RPD Project Manager at Roche Track Record: Tamiflu, Saquinavir, Tenovovir, Nelfinavir, Viread Dr. Robert Hett Managing Partner at RPD Site Manager at Carbogen Senior Scientist at Sepracor, USA Track Record: Bortezomib, Arformoterol
Impurity Profiles in Active Pharmaceutical Ingredients
Impurity Profiles in Active Pharmaceutical Ingredients EU/Swissmedic GMP Workshop Beijing University, Sept. 20 22, 2006 Dr. Susanne Keitel Federal Institute for Drugs and Medical Devices (BfArM), Germany
More informationWhat s New with Impurities in Pharmaceuticals?
What s New with Impurities in Pharmaceuticals? Southern California Pharmaceutical Discussion Group January 15, 2015 Bernard A. Olsen, Ph.D Olsen Pharmaceutical Consulting, LLC bolsen@comcast.net ICH Q3
More informationGeneral Principles for the Safety Assessment of Excipients
General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how
More informationEDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE
EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP IMPURITIES 1 Workshop Session IMPURITIES DNA-reactive impurities: An
More informationASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC)
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationMutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy
Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy Ella Smoraczewska Lhasa Limited Sales Executive Presentation utline Background & Case Study Regulatory Perspective MI Purge
More informationTYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS
TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS By Rajkumar Gupta, Managing Director Perfect Pharmaceutical Consultant Pvt. Ltd and Director Global Institute of Regulatory affairs,
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationPublic Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC
Public Assessment Report Scientific discussion Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Krka. The procedure
More informationControl of Impurities in the European Pharmacopoeia Principles and update on new developments
Control of Impurities in the European Pharmacopoeia Principles and update on new developments Dr. Michael Wierer Deputy Head, European Pharmacopoeia Department, EDQM, Council of Europe Contents 1. Principles
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationElastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen. -Senior Manager Biotechnology-
Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen -Senior Manager Biotechnology- 2005 by West Pharmaceutical Services, Inc., Lionville, PA All rights reserved.
More informationPublic Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921
Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of
More informationPublic Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680
Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of
More informationDrug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99
Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Printed in the USA. All rights reserved. Copyright 1999 Drug Information Association Inc. THE ACTIVE PHARMACEUTICAL INGREDIENTS STARTING
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationRegulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.
Regulatory Expectations for GMP: What s Happening Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Topics Background for changes and expectations of regulatory
More informationDerek Nexus and Sarah Nexus: working together for ICH M7
Derek Nexus and Sarah Nexus: working together for ICH M7 European ICGM, September 2014 Dr Nicholas Marchetti Product Manager nik.marchetti@lhasalimited.org Derek Nexus and Sarah Nexus: working together
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationFRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT VIRBAKOR 20 mg film-coated tablet for dogs Date: 03/11/2014 French agency for food, environnemental
More informationAquagent. Pyridine-free volumetric Karl Fischer reagents
Aquagent. Pyridine-free volumetric Karl Fischer reagents One-component reagents Two-component reagents Reagents for aldehyde and ketone analysis Working Media Dry solvents Standards Pyridine-free Fast
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
More informationPublic Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498
Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was
More informationstability studies in pharmaceutical development Kathy Waddle, MS Wei Pan, Ph.D. RAC Catalent Pharma Solutions
stability studies in pharmaceutical development Kathy Waddle, MS Wei Pan, Ph.D. RAC Catalent Pharma Solutions Agenda Overview of stability studies during drug product Lifecycle Stability considerations
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationThe FDA/CDER Chemical Informatics Program
The FDA/CDER Chemical Informatics Program Naomi Kruhlak, PhD Lead, Chemical Informatics Program Division of Applied Regulatory Science Office of Clinical Pharmacology Office of Translational Sciences FDA
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationA FDA Perspective on Nanomedicine Current Initiatives in the US
A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationGuidance for Industry
Guidance for Industry Q3C Tables and List U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More informationPublic Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007
Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the
More informationPublic Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark
Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval
More informationProduct list Magnesium, Calcium and further mineral compounds
Product list Magnesium, Calcium and further mineral compounds Product list Magnesium, Calcium and further mineral compounds A Aluminium stearate Aluminium sulphate C Calcium acetate Calcium ascorbate L-Calcium
More informationHigh Performance Dry Binding with CELNY-SSL Super Fine Powder
CELNY TM hydroxypropyl cellulose for nutraceutical & food use NOTE #: APPLICATION: CELNY-SSL-SFP-1 Direct Compression/ ODT Formulation High Performance Dry Binding with CELNY-SSL Super Fine Powder APPLICATION
More informationPublic Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
More informationControl Strategy Case Studies
Control Strategy Case Studies Vance Novack, GSK Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing, China, Dec 2008 Control Strategy Case Studies The information and knowledge
More informationANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS
VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationEffect of Filler Type on the Stability of Polyethylene Oxide in a Hydrophilic Matrix Tablet
Effect of Filler Type on the Stability of Polyethylene Oxide in a Hydrophilic Matrix Tablet Jennifer L Hote-Gaston (jlhote@dow.com) and Dave Wallick The Dow Chemical Company, Dow Wolff Cellulosics, Larkin
More informationGuidance for Industry
Guidance for Industry Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation
More informationREPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR)
REPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR) Principles for the handling of traces of impurities and/or contaminants in cosmetic products Report is: 1 [Choose One] Prepared For ICCR
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationCTD Dossier Preparation. Sr.Manager-Regulatory Affairs
CTD Dossier Preparation K. Srikantha Reddy Sr.Manager-Regulatory Affairs Medreich Limited Srikanth.k@medreich.com CTD Dossier Preparation CTD (Common Technical Document) contains 5 modules Module 1 Module
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationQ8(R2): Pharmaceutical Development
ICH-GCG ASEAN Q8(R2): Pharmaceutical Development Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference
More informationIntroduction to Enteris BioPharma
Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based
More informationLiposome Drug Products
Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry DRAFT GUIDANCE This guidance document is being
More informationLacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken
More informationGuidance for Industry
Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More information100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS
100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS Mr. R.M. Gupta (M. Pharm.), is a free lancer consultant for US DMF, COS, ANDA, ACTD, CTD, ectd and he is also the director of
More informationWelcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers!
Welcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers! The Founder s Vision 1992: Dr. Peter Gockel develops synthesis routes of future Active Pharmaceutical Ingredients at the
More informationHAZARDOUS CHEMICAL WASTE DISPOSAL SECTION 7
HAZARDOUS CHEMICAL WASTE DISPOSAL According to Ontario environmental legislation, generators of hazardous waste are responsible for properly packaging and labelling such wastes. The University of Toronto
More informationHow To Test For Leachables
Current FDA Perspective on Leachable Impurities in Parenteral and Ophthalmic Drug products AAPS Workshop on Pharmaceutical Stability Scientific and Regulatory Considerations for Global Drug Development
More informationQbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance
QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance Dr Amina Faham (Dow), Dr Liz Meehan (AstraZeneca) ExcipientFest, Amsterdam NL June 24, 2014 What do you understand
More informationGUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au
More informationApplications of Organic Solvent Nanofiltration in the Process Development of Active Pharmaceutical Ingredients. Dominic Ormerod
Applications of rganic Solvent Nanofiltration in the Process Development of Active Pharmaceutical Ingredients Dominic rmerod Introduction A non-thermal solvent exchange. Removal of Excess reagents via
More informationA declaration form should be completed online, printed and signed by persons applying for entry to the PME.
Page 1 of 10 Professional Master of Education Subject Declaration Form IMPORTANT This declaration form should be returned to the PME provider(s) to which you have applied or the Postgraduate Applications
More informationGuidance for Industry
Guidance for Industry Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationGUIDELINE FOR ELEMENTAL IMPURITIES
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE GUIDELINE FOR ELEMENTAL IMPURITIES Q3D Current Step 2b version
More informationINCOMPATIBILITY OF COMMON LABORATORY CHEMICALS
INCOMPATIBILITY OF COMMON LABORATORY CHEMICALS When certain hazardous chemicals are stored or mixed together, violent reactions may occur because the chemicals are unsuitable for mixing, or are incompatible.
More informationGuidance for Industry
Guidance for Industry Changes to an Approved NDA or ANDA U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) April 2004 CMC Revision
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
1 2 3 10 March 2015 EMA/HMPC/71049/2007 Rev. 2 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 Guideline on the use of the CTD format in the preparation of a registration application for traditional
More informationCleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
More informationLaboratory Hazardous Waste Disposal Guidelines
Satellite Accumulation Area (SAA) For safety and environmental reasons, hazardous waste must be stored in a designated "Satellite Accumulation Area." These areas must be inspected weekly for container
More informationOverview of Pre-Approval Inspections
Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval
More informationQbD Considerations for Analytical Methods - FDA Perspective
QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug
More informationBiological importance of metabolites. Safety and efficacy aspects
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationRe: GRAS Notice No. AGRN 000-009
May 4, 2012 Dr. Hardy Edwards III Vitamin Derivatives, Inc. 625 Lem Edwards Road Winterville, Georgia 30683 Re: GRAS Notice No. AGRN 000-009 Dear Dr. Edwards: The Food and Drug Administration (FDA) is
More informationPublic Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC
Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY
More informationTHRESHOLD OF TOXICOLOGICAL CONCERN (TTC) IN RISK ASSESSMENT
THRESHOLD OF TOXICOLOGICAL CONCERN (TTC) IN RISK ASSESSMENT Prof. Em.. Dr. Robert Kroes Institute for Risk Assessment Sciences (IRAS) Utrecht University The Netherlands PQRI December 5, 2005 1 THRESHOLD
More informationIt's in the details. JOST MINERAL GUIDE
It's in the details. JOST MINERAL GUIDE Reference Guide to Jost Mineral Compounds Jost Chemical Co. manufactures a line of mineral compounds that are used in the nutritional supplement, clinical nutrition,
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationSummary Public Assessment Report. Generics
Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin
More informationT3P Propane Phosphonic Acid Anhydride
Technology StrengthS T3P Propane Phosphonic Acid Anhydride The coupling agent of the future Coupling and water removal are synthesis tools that stand at the cutting edge of purity and cost effective manufacture
More informationGuidance for Industry
Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationCENTRAL POLLUTION CONTROL BOARD Parivesh Bhawan, East Arjun Nagar Delhi-110032
CENTRAL POLLUTION CONTROL BOARD Parivesh Bhawan, East Arjun Nagar Delhi-110032 CPCB Project on Preparation of COINDS document on Pharmaceutical industry and Development of Emission standards including
More informationPublic Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01
Public Assessment Report Scientific discussion Tostrex (Testosterone) SE/H/571/01 This module reflects the scientific discussion for the approval of Tostrex. The procedure was finalised at 2006-04-07.
More informationProperties of a molecule. Absolute configuration, Cahn-Ingold Prelog. Planar, axial, topological chirality and chirality at atoms other than carbon
Key stereochemical terminology Stereochemical terminology in organic chemistry can refer to structure of a molecule or to properties of a physical sample of the molecule. It is very important to recognize
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationERDOSTEINE - MONOGRAPH.
STRUCTURAL FORMULA (±1S-(2-[N-3-(2-oxotetrahydro thienyl)]acetamido)-thioglycolic acid) C 8 H 11 NO 4 S 2 M.W. = 249.307 DESCRIPTION Color : White to ivory white Appearance : Microcrystalline powder SOLUBILITY
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationGuidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
More informationTHE PHARMACEUTICAL INDUSTRY
TE PARMACEUTICAL INDUSTRY The pharmaceutical industry in New Zealand takes the active ingredients of drugs (which are imported from overseas) and converts them into a form that can easily be given to a
More informationSummary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,
Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public
More informationPREPARATION AND EVALUATION OF STARCH PHOSPHATE- A NEW MODIFIED STARCH AS A DISINTEGRANT IN TABLET FORMULATIONS
Int. J. Chem. Sci.: 9(2), 2011, 889-899 Int. J. Chem. Sci.: ISSN 9(1), 0972-768X 2011, 1-11 www.sadgurupublications.com PREPARATIN AND EVALUATIN F STARCH PHSPHATE- A NEW MDIFIED STARCH AS A DISINTEGRANT
More informationIntelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection
52 May/June 2012 Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection by Karen Rome and Allyson McIntyre, AstraZeneca, Macclesfield, SK10 2NA, UK Quantitative analysis
More informationConsumer Products Made with Industrial Biotechnology
s Made with Industrial Biotechnology Consumer Bread Potassium bromate, a suspected cancer-causing agent at certain levels, added as a preservative and a dough strengthening agent microorganisms produces
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationName Date Class CHAPTER 1 REVIEW. Answer the following questions in the space provided.
CHAPTER 1 REVIEW Matter and Change SECTION 1 SHORT ANSWER Answer the following questions in the space provided. 1. a Technological development of a chemical product often (a) lags behind basic research
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2010, 2(5): 548-554 Formulation and stabilization of Atorvastatin
More informationIMPURITIES AND ITS IMPORTANCE IN PHARMACY
IMPURITIES AND ITS IMPORTANCE IN PHARMACY S. Lakshmana Prabu 1*, T.N.K. Suriyaprakash 2 1 Department of Pharmaceutical Technology, Anna University-Tiruchirappalli, Tiruchirappalli 620 024. 2 Department
More information